Table of Contents

State/Territory Name: Washington

State Plan Amendment (SPA) #: 22-0019

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



July 29, 2022

Susan Birch, Director Dr. Charissa Fotinos, Medicaid Director Health Care Authority PO Box 45502 Olympia, WA 98504-5010

Re: Washington State Plan Amendment (SPA) WA-22-0019

Dear Susan Birch and Dr. Fotinos:

The Centers for Medicare & Medicaid Services (CMS) reviewed the proposed Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) WA-22-0019. This amendment ensures the required coverage of COVID-19 vaccines and vaccine administration, testing, and, treatment in accordance with the American Rescue Plan Act.

Pursuant to section 1135(b)(5) of the Social Security Act (the Act), for the period of the public health emergency, CMS is modifying the requirement at 42 C.F.R. §430.20 that the state submit SPAs related to the COVID-19 public health emergency by the final day of the quarter, to obtain a SPA effective date during the quarter, enabling SPAs submitted after the last day of the quarter to have an effective date in a previous quarter, but no earlier than the effective date of the public health emergency.

The State of Washington also requested a waiver to modify the public notice requirements applicable to the SPA submission process. Pursuant to section 1135(b)(5) of the Act, CMS is modifying public notice requirements applicable to the SPA submission process. Public notice for SPAs is required under 42 C.F.R. §447.205 for changes in statewide methods and standards for setting Medicaid payment rates, 42 C.F.R. §447.57 for changes to premiums and cost sharing, and 42 C.F.R. §440.386 for changes to Alternative Benefit Plans (ABPs). Pursuant to section 1135(b)(5) of the Act, CMS is approving the state's request to modify these notice requirements otherwise applicable to SPA submissions.

The State of Washington also requested a waiver to modify the tribal consultation timeline applicable to this SPA submission process. Pursuant to section 1135(b)(5) of the Act, CMS is also allowing states to modify the timeframes associated with tribal consultation required under section 1902(a)(73) of the Act, including shortening the number of days before submission or conducting consultation after submission of the SPA.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations.

This letter is to inform you that Washington's Medicaid SPA Transmittal Number 22-0019 is approved effective March 11, 2021.

If you have any questions, please contact Edwin Walaszek at (212) 616-2512 or via email at Edwin.Walaszek1@cms.hhs.gov.

Sincerely,

Alissa M.
Deboy -S

Deboy -S

Date: 2022.07.29
07:40:27 -04'00'

Alissa Mooney DeBoy On Behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services

Enclosures

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES 5. FEDERAL STATUTE/REGULATION CITATION 1905(a)(4)(E), (F) of the Act 1135(g)(1)(B) of the Act 7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Attachment 7.7-A pgs 1 - 3 (all new) Attachment 7.7-B pgs 1 - 3 (all new) Attachment 7.7-C pgs 1 - 3 (all new)	1. TRANSMITTAL NUMBER 2 2 — 0 0 1 9 W A 3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL SECURITY ACT XIX XXI 4. PROPOSED EFFECTIVE DATE March 11, 2021 6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a FFY 2021 \$ 124,488,226 b. FFY 2022 \$ 255,090,700 8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)
9. SUBJECT OF AMENDMENT COVID Vaccines, Testing, & Treatment (CMS preprints)	
COVID Vaccines, Testing, & Treatment (CMS preprints)	
10. GOVERNOR'S REVIEW (Check One)	
GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED: Exempt
ATE AGENCY OFFICIAL	5. RETURN TO
on behalf of	State Plan Coordinator
12. TYPED NAME	POB 42716 Dlympia, WA 98504-2716
Charissa Fotinos MD, MSc 13. TITLE	
Acting Medicaid Director	
14. DATE SUBMITTED	
May 9, 2022 FOR CMS U	DE ONLY
	7. DATE APPROVED
May 9, 2022	July 29, 2022
PLAN APPROVED - ON	
	9. SIGNATURE OF APPA CSAB CONFICI AL Deboy -S Date: 2022.07.29
March 11, 2021	Deboy -S Date: 2022.07.29
20. TYPED NAME OF APPROVING OFFICIAL	1. TITLE OF APPROVING OFFICIAL
Alissa Mooney DeBoy	On Behalf of Anne Marie Costello, Deputy Director, CMCS
22. REMARKS	

Vaccine and Vaccine Administration at Section 1905(a)(4)(E) of the Social Security Act

During the period starting March 11, 2021, and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

<u>overage</u>
X The state assures coverage of COVID-19 vaccines and administration of the vaccines.1
X The state assures that such coverage:
 Is provided to all eligibility groups covered by the state, including the optional Individuals Eligible for Family Planning Services, Individuals with Tuberculosis, and COVID-19 groups if applicable, with the exception of the Medicare Savings Program groups and the COBRA Continuation Coverage group for which medical assistance consists only of payment of premiums; and Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(H) and section 1916A(b)(3)(B)(xii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
\underline{X} Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing or similar charge, pursuant to section 1937(b)(8)(A) of the Act.
X The state provides coverage for any medically necessary COVID-19 vaccine counseling for children under the age of 21 pursuant to §§1902(a)(11), 1902(a)(43), and 1905(hh) of the Act.
X The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration, with respect to the providers that are considered qualified to prescribe, dispense, administer, deliver and/or distribute COVID-19 vaccines.
Additional Information (Optional):

TN# <u>22-0019</u> Supersedes: <u>NEW</u> Approval Date: <u>7/29/2022</u> Effective Date: <u>3/11/2021</u>

¹ The vaccine will be claimed under this benefit once the federal government discontinues purchasing the vaccine.

Reimbursement

TN# <u>22-0019</u> Approval Date: <u>7/29/2022</u> Effective Date: <u>3/11/2021</u>

The payment methodologies for COVID-19 vaccines and the administration of the vaccines for providers listed above are described below:
The state is establishing rates for any medically necessary COVID-19 vaccine counseling for children under the age of 21 pursuant to sections $1905(a)(4)(E)$, $1905(r)(1)(B)(v)$ and $1902(a)(30)(A)$ of the Act.
The state's rate is as follows and the state's fee schedule is published in the following location

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN# <u>22-0019</u> Approval Date: <u>7/29/2022</u> Effective Date: <u>3/11/2021</u>

COVID-19 Testing at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021, and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage

X The states assures coverage of COVID-19 testing consistent with the Centers for Disease Control
and Prevention (CDC) definitions of diagnostic and screening testing for COVID-19 and its
recommendations for who should receive diagnostic and screening tests for COVID-19.

- X The state assures that such coverage:
 - 1. Includes all types of FDA authorized COVID-19 tests;
 - 2. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
 - 3. Is provided to the optional COVID-19 group if applicable; and
 - 4. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

Please describe any limits on amount, duration or scope of COVID-19 testing consistent with 42 CFR 440.230(b).

Limited to 12 tests per month for; COVID PCR, antigen and OTC tests. Limited to one test per year for COVID antibody tests. The amounts can be exceeded with prior authorization (known as a limitation extension).

authorization (known as a limitation extension).	
X	-
Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or sime charge, pursuant to section 1937(b)(8)(B) of the Act.	ila
\underline{X} The state assures compliance with the HHS COVID-19 PREP Act declarations and authorization ncluding all of the amendments to the declaration.	ıs,
Additional Information (Optional):	
	⅃

TN# <u>22-0019</u> Approval Date: <u>7/29/2022</u> Effective Date: <u>3/11/2021</u>

Reimbursement

X The state assures that it has established state plan rates for COVID-19 testing consistent with the CDC definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 testing for each applicable Medicaid benefit:

	COVID-19 testing rates were established using the methodology described in Attachment 4.19-B III Physician Services
	The state is establishing rates for COVID-19 testing pursuant to pursuant to sections 1905(a)(4)(F) 02(a)(30)(A) of the Act.
	he state's rates for COVID-19 testing are consistent with Medicare rates for testing, including any Medicare updates at the:
	Medicare national average, OR
	Associated geographically adjusted rate.
	he state is establishing a state specific fee schedule for COVID-19 testing pursuant to sections)(4)(F) and 1902(a)(30)(A) of the Act.
The sta	ate's rate is as follows and the state's fee schedule is published in the following location:

TN# <u>22-0019</u> Approval Date: 7/29/2022 Effective Date: <u>3/11/2021</u>

X The state's fee schedule is the same for all governmental and private providers.

The below listed providers are paid differently from the above rate schedules and payment to thes providers for COVID-19 testing is described under the benefit payment methodology applicable to the provider type:	е
Additional Information (Optional):	
The payment methodologies for COVID-19 testing for providers listed above are described below:	

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

TN# <u>22-0019</u> Approval Date: <u>7/29/2022</u> Effective Date: <u>3/11/2021</u>

COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021, and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

Coverage for the Treatment and Prevention of COVID

Additional Information (Optional):

X The states ass (including preventiv	ures coverage of COVID-19 treatment, including specialized equipment and therapies e therapies).
X The st	ate assures that such coverage:
1.	Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19;
2.	Includes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
3.	Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19;
4.	Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
5.	Is provided to the optional COVID-19 group, if applicable; and
6.	Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
	_ Applies to the state's approved Alternative Benefit Plans, without any deduction, cost aring, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
	te assures compliance with the HHS COVID-19 PREP Act declarations and ons, including all of the amendments to the declaration.

Coverage for a Condition that May Seriously Complicate the Treatment of COVID

X The states assures coverage of treatment for a condition that may seriously complicate the treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to have COVID-19.
X The state assures that such coverage:
 Includes items and services, including drugs, that were covered by the state as of March 11, 2021;
 Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes;
 Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
 Is provided to the optional COVID-19 group, if applicable; and Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.
\underline{X} Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.
X_The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.
Additional Information (Optional):
Reimbursement .
\underline{X} The state assures that it has established state plan rates for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).
List references to Medicaid state plan payment methodologies that describe the rates for COVID- 19 treatment for each applicable Medicaid benefit:
COVID-19 testing rates were established using the methodology described in Attachment 4.19-B III Physician Services
The state is establishing rates or fee schedule for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies) pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.

Attachment 7.7-C Page 3

	providers. The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider
	type:
L	
onal Info	ormation (Optional):

PRA Disclosure Statement Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.